JP2022537019A5 - - Google Patents
Info
- Publication number
- JP2022537019A5 JP2022537019A5 JP2021571689A JP2021571689A JP2022537019A5 JP 2022537019 A5 JP2022537019 A5 JP 2022537019A5 JP 2021571689 A JP2021571689 A JP 2021571689A JP 2021571689 A JP2021571689 A JP 2021571689A JP 2022537019 A5 JP2022537019 A5 JP 2022537019A5
- Authority
- JP
- Japan
- Prior art keywords
- agonist
- binding molecule
- psma
- antigen
- bispecific antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024144403A JP2024164199A (ja) | 2019-06-21 | 2024-08-26 | Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864999P | 2019-06-21 | 2019-06-21 | |
| US62/864,999 | 2019-06-21 | ||
| PCT/US2020/038786 WO2020257681A1 (en) | 2019-06-21 | 2020-06-19 | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144403A Division JP2024164199A (ja) | 2019-06-21 | 2024-08-26 | Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537019A JP2022537019A (ja) | 2022-08-23 |
| JP2022537019A5 true JP2022537019A5 (enExample) | 2023-06-21 |
| JP7743313B2 JP7743313B2 (ja) | 2025-09-24 |
Family
ID=71528054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571689A Active JP7743313B2 (ja) | 2019-06-21 | 2020-06-19 | Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
| JP2024144403A Pending JP2024164199A (ja) | 2019-06-21 | 2024-08-26 | Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144403A Pending JP2024164199A (ja) | 2019-06-21 | 2024-08-26 | Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200399372A1 (enExample) |
| EP (1) | EP3986933A1 (enExample) |
| JP (2) | JP7743313B2 (enExample) |
| KR (1) | KR20220024594A (enExample) |
| CN (2) | CN118526580A (enExample) |
| AU (1) | AU2020296181A1 (enExample) |
| CA (1) | CA3139827A1 (enExample) |
| IL (1) | IL289041A (enExample) |
| MA (1) | MA56515A (enExample) |
| MX (1) | MX2021015271A (enExample) |
| WO (1) | WO2020257681A1 (enExample) |
| ZA (1) | ZA202109048B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240139065A (ko) * | 2022-02-07 | 2024-09-20 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Psma 및 cd3에 특이적으로 결합하는 항원 결합 분자 및 이들의 의약적 용도 |
| WO2023224912A1 (en) * | 2022-05-16 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
| WO2025070636A1 (ja) * | 2023-09-26 | 2025-04-03 | ブライトパス・バイオ株式会社 | Ｃｄ３９を標的とする多重特異性抗原結合性分子 |
| CN118086511B (zh) * | 2024-04-25 | 2024-07-09 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | 胃粘膜肠上皮化生亚型生物标志物folh1及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5428156A (en) | 1993-04-02 | 1995-06-27 | Associated Universities, Inc. | Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| IL263466B2 (en) * | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| EP3131585B1 (en) | 2014-03-19 | 2020-07-15 | Universität Zürich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
| RU2743781C2 (ru) * | 2014-06-10 | 2021-02-25 | 3Б Фармасьютикалз Гмбх | Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение |
| US9980930B2 (en) * | 2014-10-16 | 2018-05-29 | The University Of Melbourne | Imaging composition and uses thereof |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| AU2016325630B2 (en) * | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| KR20180096789A (ko) * | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| EP4649966A3 (en) * | 2016-12-01 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| AU2017380981B2 (en) * | 2016-12-19 | 2025-01-30 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1BB (CD137) agonists |
| KR102692708B1 (ko) * | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법 |
| CN112210010B (zh) * | 2017-01-06 | 2023-12-05 | 优特力克斯有限公司 | 抗-人4-1bb抗体及其应用 |
| CN113286811B (zh) * | 2018-07-30 | 2024-12-06 | 南加利福尼亚大学 | 改善过继性细胞疗法的效力和安全性 |
-
2020
- 2020-06-19 CN CN202410406265.5A patent/CN118526580A/zh active Pending
- 2020-06-19 MX MX2021015271A patent/MX2021015271A/es unknown
- 2020-06-19 JP JP2021571689A patent/JP7743313B2/ja active Active
- 2020-06-19 CN CN202080045496.8A patent/CN114025802B/zh active Active
- 2020-06-19 CA CA3139827A patent/CA3139827A1/en active Pending
- 2020-06-19 AU AU2020296181A patent/AU2020296181A1/en active Pending
- 2020-06-19 MA MA056515A patent/MA56515A/fr unknown
- 2020-06-19 WO PCT/US2020/038786 patent/WO2020257681A1/en not_active Ceased
- 2020-06-19 US US16/906,943 patent/US20200399372A1/en active Pending
- 2020-06-19 KR KR1020227001447A patent/KR20220024594A/ko active Pending
- 2020-06-19 EP EP20737787.0A patent/EP3986933A1/en active Pending
-
2021
- 2021-11-12 ZA ZA2021/09048A patent/ZA202109048B/en unknown
- 2021-12-15 IL IL289041A patent/IL289041A/en unknown
-
2024
- 2024-08-26 JP JP2024144403A patent/JP2024164199A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537019A5 (enExample) | ||
| JP2022537269A5 (enExample) | ||
| KR102349056B1 (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
| Chu et al. | Cell surface self-assembly of hybrid nanoconjugates via oligonucleotide hybridization induces apoptosis | |
| JP2022078265A (ja) | 肺癌の処置のための抗ｐｄ－１抗体 | |
| JP2021519076A5 (enExample) | ||
| JP2018502120A5 (enExample) | ||
| JP2021513844A5 (enExample) | ||
| JP2019533475A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| JP2022528030A5 (enExample) | ||
| TW201311274A (zh) | 包含抗－ｃｄ１９類美登素（ｍａｙｔａｎｓｉｎｏｉｄ）免疫結合物及利妥昔單抗（ｒｉｔｕｘｉｍａｂ）之用於治療ｃｄ１９＋ｂ－細胞惡性症狀之組合療法 | |
| JP2022543765A5 (enExample) | ||
| JP7851684B2 (ja) | Ｅｍｔ経路を遮断してがん幹細胞を克服するｉｌ８ | |
| JP2024540275A5 (enExample) | ||
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| JP2025501978A5 (enExample) | ||
| Montes De Oca et al. | PF558 THE ANTI‐BCMA ANTIBODY‐DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE‐MEDIATED ANTI‐TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY | |
| JP2025515092A5 (enExample) | ||
| JP2011505371A5 (enExample) | ||
| JP2023505222A5 (enExample) | ||
| WO2019214492A1 (zh) | 抗her2抗体-药物偶联物在治疗癌症中的用途 | |
| Zhou et al. | Clinical results of a phase 1 trial evaluating a HER2 directed CAR-T product selective for the tumor microenvironment (TME) in patients with GI and other solid tumor malignancies | |
| WO2001052889A1 (fr) | Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers | |
| RU2021132847A (ru) | Применение биспецифических антигенсвязывающих молекул, которые связывают psma и cd3, в комбинации с костимуляцией 4-1bb |